高龄非瓣膜性房颤的华法林治疗11例体会

目的:探讨华法林治疗高龄非瓣膜性房颤患者安全有效的抗凝强度。方法:对11例高龄非瓣膜房颤有抗凝适应证者予华法林治疗,将抗凝强度控制在INR为1.5~2.0,观察疗效和出血并发症。结果:观察期间11例患者无致命性出血,仅1例皮肤出血且未停药。7例患者反复发作的短暂性脑缺血发作和脑梗塞症状得到控制。3例有2种以上危险因素的患者未出现栓塞并发症。结论:低抗凝强度(INR1.5~2.0)抗凝对高龄非瓣膜性房颤患者安全有效。

Experiences of warfarin therapy for 11 senile patients with non-valvular atrial fibrillation

Objective:To discuss the safety and effectiveness of the anticoagulant intensity of warfarin therapy for senilepatients with non-valvular atrial fibrillation(AF).Methods:The 11 senile patients with AF had been selected for the anticoagulant warfarin therapy.The anticoagulant intensity had been controlled between INR 1.5~2.0.The effectiveness of the treatment and the bleeding manifest was observed.Results:None of the 11 patientshad the symptomof lethal hemorrhage;but one patient had the cutis bleeding and the medication wasn't terminated after this manifestoccurred.The symptoms of 7 patients who had recurrent transient ischemic attack(TIA) and ischemic stroke,had been control during the treatment.There were no thromboembolic complicationsfor the other 3 patients who had more than two risk factors.Conclusion:Warfarin therapyis safe and effective for the senile patients with non-valvular atrial fibrillation when controlling the anticoagulant intensity between INR 1.5~2.0.